Recent advances in diagnosis and treatment of hemophilia and related diseases

References

• Brinkhous K. M. Plasma prothrombin: vitamin K. Medicine 1940; 19: 329
   Google Scholar
• Campbell H. A., Link K. P. Studies on the hemorrhagic sweet clover disease. J. Biol. Chem. 1941; 138: 21
   Google Scholar
• Brinkhous K. M., Langdell R. D., Wagner R. H. Hemostatic disorders: hemophilia and the hemophilioid diseases. Ann. Rev. Med. 1958; 9: 159
   PubMedGoogle Scholar
• Lee R. I., White P. D. A clinical study of the coagulation time of blood. Amer. J. Med. Sci. 1913; 145: 495
   Google Scholar
• Langdell R. D. Transfusion therapy in hemophilia. Hemophilia and Hemophilioid Diseases, K. M. Brinkhous. Univ. of North Carolina Press, Chapel Hill 1957
   Google Scholar
• Quick A. J., Stanley‐Brown M., Bancroft F. W. Study of the coagulation defect in hemophilia and in jaundice. Amer. J. Med. Sci. 1935; 190: 501
   Google Scholar
• Warner E. D., Brinkhous K. M., Smith H. P. The titration of prothrombin in certain plasmas. Arch. Path. 1934; 18: 587
   Google Scholar
• Brinkhous K. M. Clotting defects in hemophilia: deficiency in a plasma factor required for platelet utilization. Proc. Soc. Exp. Biol. Med. 1947; 66: 117
   PubMed Web of Science ®Google Scholar
• Quick A. J., Favre‐Gilly J. E. Fibrin, a factor influencing the consumption of prothrombin in coagulation. Amer. J. Physiol. 1949; 158: 387
   PubMedGoogle Scholar
• Langdell R. D., Graham J. B., Brinkhous K. M. Prothrombin utilization during clotting: comparison of results with the two‐stage and one‐stage method. Proc. Soc. Exp. Biol. Med. 1950; 74: 424
   PubMedGoogle Scholar
• Buckwatler J. A., Blythe W. B., Brinkhous K. M. Effect of blood platelets on prothrombin utilization of dog and human plasmas. Amer. J. Physiol. 1949; 159: 316
   PubMedGoogle Scholar
• Graham J. B., Collins D. L., Godwin I. D., Brinkhous K. M. Assay of plasma antihemophilic activity in normal heterozygous and prothrombinopenic dogs. Proc. Soc. Exp. Biol. Med. 1951; 77: 294
   PubMedGoogle Scholar
• Quick A. J. Studies on the enigma of hemostatic dysfunction of hemophilia. Amer. J. Med. Sci. 1947; 214: 272
   PubMed Web of Science ®Google Scholar
• Langdell R. D., Wagner R. H., Brinkhous K. M. Effect of antihemophilic factor on one‐stage clotting tests. J. Lab. Clin. Med. 1953; 41: 637
   PubMed Web of Science ®Google Scholar
• Brinkhous K. M., Langdell R. D., Penick G. D., Graham J. B., Wagner R. H. Newer approaches to the study of hemophilia and hemophilioid states. J.A.M.A. 1954; 154: 481
   PubMedGoogle Scholar
• Langdell R. D. Laboratory diagnosis of hemorrhagic disorder. South. Med. J. 1961; 54: 560
   PubMedGoogle Scholar
• Nye S. W., Graham J. B., Brinkhous K. M. The partial thromboplastin time as a screening test for the detection of latent bleeders. Amer. J. Med. Sci. 1962; 243: 279
   PubMedGoogle Scholar
• Ratnoff O. D., Crum J. D. Activation of Hageman factor by solutions of ellagic acid. J. Lab. Clin. Med. 1964; 63: 359
   PubMed Web of Science ®Google Scholar
• Biggs R., Douglas A. S. The thromboplastin generation test. J. Clin. Path. 1953; 6: 23
   PubMed Web of Science ®Google Scholar
• Rodman N. F., Jr., Barrow E. M., Graham J. B. Diagnosis and control of the hemophilioid states with the partial thromboplastin time (PTT) test. Amer. J. Clin. Path. 1958; 29: 525
   PubMedGoogle Scholar
• Graham J. B., McLendon W. W., Brinkhous K. M. Mild hemophilia: allelic form of the disease. Amer. J. Med. Sci. 1953; 225: 46
   PubMedGoogle Scholar
• Brinkhous K. M., Penick G. D., Langdell R. D., Wagner R. H., Graham J. B. Physiologic basis of transfusion therapy in hemophilia. Arch. Path. 1956; 61: 6
   Google Scholar
• McMillan C. W., Personal communication
   Google Scholar
• Langdell R. D., Wagner R. H., Brinkhous K. M. Antihemophilic factor (AHF) levels following transfusion of blood, plasma and plasma fractions. Proc. Soc. Exp. Biol. Med. 1955; 88: 212
   PubMedGoogle Scholar
• Pool J. G., Shannon A. E. Production of high‐potency concentrates of antihemophilic globulin in a closed‐bag system. New Eng. J. Med. 1965; 273: 1443
   PubMed Web of Science ®Google Scholar
• Dallman P. R., Pool J. G. Treatment of hemophilia with factor VIII concentrates. New Eng. J. Med. 1968; 278: 199
   PubMed Web of Science ®Google Scholar
• Weaver R. A., Gabriel D. A., Langdell R. D. Concentrated antihemophilic factor (AHF) from out‐dated blood. Transfusion. 1967; 7: 168
   PubMedGoogle Scholar
• Cohn E. J., Strong L. E., Hughes W. L., Mulford D. J., Ashworth J. N., Melin M., Taylor H. L. Preparation and Properties of Serum and Plasma Proteins IV. A System for the Separation into Fractions of the Protein and Lipoprotein Components of Biological Tissues and Fluids. J. Amer. Chem. Soc. 1946; 68: 459
   PubMed Web of Science ®Google Scholar
• Kekwick R. A., Mackay M. E., Nance M. H., Record B. R. The purification of human fibrinogen. Biochem. J. 1955; 60: 671
   PubMedGoogle Scholar
• Bidwell E. The purification of bovine antihemophilic globulin. Brit. J. Haemat. 1955; 1: 35
   PubMedGoogle Scholar
• Wagner R. H., McLester W. D., Smith M., Brinkhous K. M. Purification of antihemophilic factor (factor VIII) by amino precipitation. Thromb. Diath. Haemorrh. 1964; 11: 64
   PubMedGoogle Scholar
• Webster W. P., Roberts H. R., Thelin G. M., Wagner R. H., Brinkhous K. M. Clinical use of a new glycine‐precipitated antihemophilic fraction. Amer. J. Med. Sci. 1965; 250: 643
   PubMed Web of Science ®Google Scholar
• Johnson A. J., Karpatkin M. H., Newman J. Preparation and clinical experience with antihemophilic factor concentrates. Thromb. Diath. Haemorrh., Suppl. 1969; 35: 49
   Google Scholar
• Bidwell E. The purification of antihemophilic globulin from animal plasma. Brit. J. Haemat. 1955; 1: 386
   PubMedGoogle Scholar
• Rizza C. R., Biggs R. The use of plasma fractions in the treatment of hemophilia and von Willebrand's disease. Progr. Hemat. 1969; Vol. 6: 181
   Google Scholar
• McNicol G. P., Fletcher A. P., Alkjaersig N., Sherry S. The use of epsilon aminocaproic acid, a potent inhibitor of fibrinolytic activity in the management of post operative hematuria. J. Urol. 1961; 86: 829
   Google Scholar
• Abe T., Sate A., Kazama M., Matsumura T. Effect of e‐Aminocaproic acid in hemophilia. Lancet 1962; 2: 405
   Google Scholar
• Stark S. N., White J. G., Langer L., Jr., Krivit W. Epsilon amino caproic acid therapy as a cause of intrarenal obstruction in haematuria of haemophilics. Scand. J. Haemat. 1965; 2: 99
   PubMedGoogle Scholar
• Roberts H. R., Scales M. D., Madison J. T., Webster W. P., Penick G. D. A clinical and experimental study of acquired inhibitors to factor VIII. Blood 1965; 26: 805
   PubMed Web of Science ®Google Scholar
• Hougie C. Studies on an acquired anticoagulant directed against factor VIII. J. Lab. Clin. Med. 1967; 70: 384
   PubMedGoogle Scholar
• Shapiro S. S. The immunologic character of acquired inhibitors of antihemophilic globulin (factor VIII) and the kinetics of their interactions with factor VIII. J: Clin. Invest. 1967; 46: 147
   PubMedGoogle Scholar
• Margolius A., Jr., Jackson D. P., Ratnoff D. D. Circulating anticoagulants: a study of 40 cases and a review of the literature. Medicine 1961; 40: 145
   PubMed Web of Science ®Google Scholar
• Sise H. S., Gauthier J., Desforges J., Becker R. Spontaneous circulating anticoagulant (antifactor 8). Amer. J. Med. 1962; 32: 964
   PubMed Web of Science ®Google Scholar
• Soulier J. P., Menache D., Steinbuch M., Blatrix Ch., Josso F. Preparation of clinical use of P.P.S.B. (factors II, VII, X and IX concentrate). Thromb. Diath. Haemorrh. 1969; 61(Suppl. 35)
   Google Scholar
• McKay D. G. Disseminated intravascular coagulation: an intermediary mechanism of disease. Hoeber‐Harper, New York 1965
   Google Scholar
• Merskey C., Johnson A. J., Kleiner G. J., Wohl H. The defibrination syndrome: clinical features and laboratory diagnosis. Brit. J. Haemat. 1967; 13: 528
   PubMed Web of Science ®Google Scholar